v3.26.1
Note 2 - Summary of Significant Accounting Policies - Net Income Per Ordinary Share (Details) - USD ($)
 1 Months Ended 3 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Basic weighted-average shares outstanding (in shares) 100 100        
Diluted weighted-average shares outstanding (in shares) 100 100        
Basic and diluted net loss per share of common stock (in dollars per share) $ (6.59) $ (372.69)        
Basic and diluted net loss per share of common stock (in dollars per share) $ (6.59) $ (372.69)        
Archimedes Tech SPAC Partners II Co | Redeemable Ordinary Shares [Member]            
Allocation of net income (loss)   $ 1,325,126 $ 782,843   $ 6,071,015  
Allocation of net income, diluted   $ 1,325,126 $ 767,735   $ 6,051,450  
Basic weighted-average shares outstanding (in shares)   23,000,000 12,146,067 0 20,290,411  
Diluted weighted-average shares outstanding (in shares)   23,000,000 12,146,067   20,290,411  
Basic and diluted net loss per share of common stock (in dollars per share)   $ 0.06 $ 0.06 $ 0 $ 0.3  
Basic and diluted net loss per share of common stock (in dollars per share)   $ 0.06 $ 0.06   $ 0.3  
Archimedes Tech SPAC Partners II Co | Non-redeemable Ordinary Shares [Member]            
Allocation of net income (loss)   $ 379,677 $ 376,380   $ 1,915,723 $ (78,700)
Allocation of net income, diluted   $ 379,677 $ 391,488   $ 1,935,288 $ (78,700)
Basic weighted-average shares outstanding (in shares)   6,590,000 5,839,663 5,000,000 [1] 6,402,685 [1] 5,000,000
Diluted weighted-average shares outstanding (in shares)   6,590,000 6,193,596 5,000,000 [1] 6,488,986 [1] 5,000,000
Basic and diluted net loss per share of common stock (in dollars per share)   $ 0.06 $ 0.06 $ (0.02) $ 0.3 $ (0.02)
Basic and diluted net loss per share of common stock (in dollars per share)   $ 0.06 $ 0.06 $ (0.02) $ 0.3 $ (0.02)
[1] Prior to the Company’s Initial Public Offering, the ordinary shares excluded an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.